Breast cancer cases may benefit from therapies that blockade the EZH2-CCL2/CCR2 cell revulsive axis or its amplifier IL-10-EGFR pathway for the alleviation of cancer growth and dissemination. Here, CCL2 is linked to breast carcinoma.